14 April 2023 - Indications under review include prevention of respiratory syncytial virus in infants from birth through 6 months of age by immunisation of pregnant individuals, and in individuals 60 years of age and older.

Pfizer Canada announced today that Health Canada has accepted for review the new drug submission for its bivalent respiratory syncytial virus vaccine.

Read Pfizer press release